Thursday, July 27, 2017 7:19:01 PM
Gene-based immunotherapy targeting a range of cancers
Status: Pre–Clinical complete
Immunotherapy
OXB-302 is a gene-based cancer immunotherapy targeting a wide range of tumours and a number of haematological malignancies.
Our approach
OXB-302 is a novel oncology product that combines Oxford BioMedica’s lentiviral vector platform and 5T4 technology platforms. This cell therapy uses the LentiVector® platform to engineer patients’ harvested T-cells to express an antibody against the 5T4 antigen, which is expressed on the cell surface in many common cancers. These T-cells are then infused back into the patient, and subsequently recognise the 5T4 tumour antigen and initiate cell killing immune mechanisms.
Proof of concept
OXB-302 has completed pre-clinical development, delivering encouraging efficacy in an industry standard in vivo tumour challenge model.
Clinical status
Following the successful completion of preclinical development, planning for a Phase I/II clinical study is well underway, with a regulatory submission anticipated in the near future.
Market opportunity
The targeted cancer treatment and immunotherapy market is forecast to grow to $36.8 billion by 2019. With a large number of cancers expressing the 5T4 antigen, OXB-302 has significant market potential if successful in any of its target indications.
http://www.oxfordbiomedica.co.uk/pipeline
Good luck and GOD bless,
George
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM